Clinical Pharmacy

[Clinical Pharmacy @PharmaClinical]

FDA Approves Zolbetuximab in Advanced CLDN18.2+ Gastric/GEJ Adenocarcinoma

https://t.co/JII4GcqoeM

[Clinical Pharmacy @PharmaClinical]

HER3-DXd Significantly Improves PFS Vs Chemo in Advanced EGFR+ NSCLC

https://t.co/Ii8frmXFZh

[Clinical Pharmacy @PharmaClinical]

FDA Approves Subcutaneous Daratumumab Regimen in Newly Diagnosed Multiple Myeloma
https://t.co/lbAe4GM5xe

[Clinical Pharmacy @PharmaClinical]

Can Mutations in DNA Damage Repair Genes Predict Cisplatin Response in Muscle-Invasive Urothelial Carcinoma?

https://t.co/VzyFR6BKsF

[Clinical Pharmacy @PharmaClinical]

FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma

https://t.co/bkLc2yF21U

[Clinical Pharmacy @PharmaClinical]

https://t.co/MrY9dtImNJ

[Clinical Pharmacy @PharmaClinical]

Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival | NEJM Evidence
https://t.co/BidrkVy9j4

[Clinical Pharmacy @PharmaClinical]

Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study
https://t.co/I01yDbNggZ

[Clinical Pharmacy @PharmaClinical]

Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel | Blood Advances | American Society of Hematology (https://t.co/oP4ezT50lS)

[Clinical Pharmacy @PharmaClinical]

Prediction models of persistent taxane-induced peripheral neuropathy among breast cancer survivors using whole-exome sequencing | npj Precision Oncology
https://t.co/dnQDGbbLAG

[Clinical Pharmacy @PharmaClinical]

The Transcriptional Landscape of Coding and Noncoding RNAs in Recurrent and Nonrecurrent Colon Cancer
https://t.co/1V8Iz9onJ8

[Clinical Pharmacy @PharmaClinical]

Bortezomib, thalidomide & dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
https://t.co/KJgCUGN2E0

[Clinical Pharmacy @PharmaClinical]

Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial | Journal of Clinical Oncology (https://t.co/A2PUzLEwsu)

[Clinical Pharmacy @PharmaClinical]

Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non–Small Cell Lung Cancer
https://t.co/KhdvGctK7q

[Clinical Pharmacy @PharmaClinical]

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs
https://t.co/6wD6jX7dlx

[Clinical Pharmacy @PharmaClinical]

FDA Approves Radiopharmaceutical for Rare Gastrointestinal Cancers
https://t.co/3DaZ1kn9bO

[Clinical Pharmacy @PharmaClinical]

Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor–Mutated Lung Cancer: Personalization, Parsimony, and Partnership
https://t.co/EddXosN7om

[Clinical Pharmacy @PharmaClinical]

Artificial Intelligence Individualized Risk Classifier in Multiple Myeloma
https://t.co/fxxCTYNbBs

[Clinical Pharmacy @PharmaClinical]

FDA Approves Tislelizumab for Previously Treated Patients With Advanced Esophageal Cancer
https://t.co/BzGPIPYvak

[Clinical Pharmacy @PharmaClinical]

DREAMM-7 Confirms Benefit of Triplet Regimen in Relapsed or Refractory Multiple Myeloma https://t.co/MgPYrLW4lM